Skip to main content

Advertisement

Table 5 Clinical studies in other cancer types

From: Combination of CTLA-4 and PD-1 blockers for treatment of cancer

Cancer type Patients Trial, ID Follow-up Outcomes Reference
Malignant pleural mesothelioma Previously treated Phase 2 NCT03048474 > 12 months ORR, 38% Median PFS, 6.2 months 6-month PFS rate, 50% Median OS, not reached 12-month OS rate, 64% Grade 3-4 AEs, 38% Disselhorst et al 2019
Malignant pleural mesothelioma Previously treated Phase 2 NCT02716272 > 16 months ORR, 28% Median PFS, 5.6 months 12-month PFS rate, 23% Median OS rate, 15.9 months 12-month OS rate, 58% Grade 3-4 AEs, 26% Scherpereel et al 2019
Unresectable Sarcoma Previously treated Phase 2 NCT02500797 > 12 months Confirmed response, 16% Median PFS, 4.1 months Median OS, 14.3 months Grade 3-4 AEs, 14% D’Angelo et al 2018
Esophagogastric cancer Previously treated Phase 1/2 NCT01928394   Investigator assessed ORR, 24% Median PFS, 1.4 months 12-month PFS rate, 17% Median OS, 6.9 months 18-month OS rate, 28% Grade 3-4 AEs, 35% Janjigian et al 2018
Prostate cancer Previously treated, AR-V7 positive Phase 2 NCT02601014 ≥ 1.9 months ORR, 25% Median PFS,3.7 months Median OS, 8.2 months Grade 3-4 AEs, 46% Boudadi et al 2018